A review of the perioperative management of direct oral anticoagulants for pediatric anesthesiologists.

IF 1.7 4区 医学 Q2 ANESTHESIOLOGY Pediatric Anesthesia Pub Date : 2024-09-08 DOI:10.1111/pan.14983
Kara Furman, Andrew Giustini, Joshua Branstetter, Gary Woods, Laura A Downey
{"title":"A review of the perioperative management of direct oral anticoagulants for pediatric anesthesiologists.","authors":"Kara Furman, Andrew Giustini, Joshua Branstetter, Gary Woods, Laura A Downey","doi":"10.1111/pan.14983","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Although direct oral anticoagulants (DOACs) have been used in the adult population for over a decade, DOACs use has begun to rise in pediatric populations since FDA approval of rivaroxaban and dabigatran, DOACs offer several advantages for pediatric patients, to other anticoagulants, including a similar safety profile, minimal lab monitoring, and ease of administration. The rise in DOAC use has led to an increasing number of pediatric patients managed on DOACs presenting for elective and urgent procedures. Perioperative management of anticoagulation is often challenging for providers due to the lack of expert consensus guidelines and the difficulty in balancing a patient's thrombotic risk with bleeding risk for a given procedure.</p><p><strong>Aims: </strong>Using the most up to date literature, we provide a focused review on the perioperative management of DOACs in pediatric patients.</p><p><strong>Conclusions: </strong>This work presents a focused review for pediatric anesthesiologists on clinically available DOACs, perioperative monitoring and management of DOACs, as well as options and indications for reversal. While consensus expert practice guidelines are still needed, we hope this work will familiarize perioperative physicians with these agents, recommended uses, and potential perioperative management.</p>","PeriodicalId":19745,"journal":{"name":"Pediatric Anesthesia","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Anesthesia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/pan.14983","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Although direct oral anticoagulants (DOACs) have been used in the adult population for over a decade, DOACs use has begun to rise in pediatric populations since FDA approval of rivaroxaban and dabigatran, DOACs offer several advantages for pediatric patients, to other anticoagulants, including a similar safety profile, minimal lab monitoring, and ease of administration. The rise in DOAC use has led to an increasing number of pediatric patients managed on DOACs presenting for elective and urgent procedures. Perioperative management of anticoagulation is often challenging for providers due to the lack of expert consensus guidelines and the difficulty in balancing a patient's thrombotic risk with bleeding risk for a given procedure.

Aims: Using the most up to date literature, we provide a focused review on the perioperative management of DOACs in pediatric patients.

Conclusions: This work presents a focused review for pediatric anesthesiologists on clinically available DOACs, perioperative monitoring and management of DOACs, as well as options and indications for reversal. While consensus expert practice guidelines are still needed, we hope this work will familiarize perioperative physicians with these agents, recommended uses, and potential perioperative management.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
针对儿科麻醉师的直接口服抗凝剂围手术期管理回顾。
背景:尽管直接口服抗凝药(DOACs)在成人人群中使用已有十多年,但自美国食品药品管理局批准利伐沙班和达比加群后,DOACs 在儿科人群中的使用开始增加。与其他抗凝药相比,DOACs 为儿科患者提供了多项优势,包括相似的安全性、最低限度的实验室监测和易于给药。随着 DOAC 使用量的增加,越来越多的儿科患者在接受择期手术和紧急手术时使用 DOAC。由于缺乏专家共识指南,而且很难在特定手术中平衡患者的血栓风险和出血风险,因此围手术期的抗凝管理对医疗服务提供者来说往往具有挑战性。目的:利用最新文献,我们对儿科患者 DOACs 的围手术期管理进行了重点综述:这项工作为儿科麻醉医师提供了一篇关于临床可用 DOACs、DOACs 的围术期监测和管理以及逆转的选择和适应症的重点综述。虽然仍需要达成共识的专家实践指南,但我们希望这项工作能让围术期医生熟悉这些药物、推荐用途和潜在的围术期管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pediatric Anesthesia
Pediatric Anesthesia 医学-麻醉学
CiteScore
3.20
自引率
11.80%
发文量
222
审稿时长
3-8 weeks
期刊介绍: Devoted to the dissemination of research of interest and importance to practising anesthetists everywhere, the scientific and clinical content of Pediatric Anesthesia covers a wide selection of medical disciplines in all areas relevant to paediatric anaesthesia, pain management and peri-operative medicine. The International Editorial Board is supported by the Editorial Advisory Board and a team of Senior Advisors, to ensure that the journal is publishing the best work from the front line of research in the field. The journal publishes high-quality, relevant scientific and clinical research papers, reviews, commentaries, pro-con debates, historical vignettes, correspondence, case presentations and book reviews.
期刊最新文献
The power of POCUS in every pocket: Handheld ultrasound the new essential tool? Severe knotting guidewire after central venous catheterization. Ball valve gas trapping in pediatric one-lung ventilation: Not all ventilation is loss of isolation. Links between mutations in functionally separate arms of mitochondrial complex I and responses to volatile anesthetics. Feasibility of bispectral index monitoring during pediatric critical care transport.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1